Form 4: Regeneron CEO Exercises Options, Sells Shares

Regeneron Pharmaceuticals CEO Leonard S. Schleifer exercised stock options and subsequently sold shares to cover tax obligations.

Summary

• Leonard S. Schleifer, Board Co-Chair, President & CEO of Regeneron Pharmaceuticals, Inc. (REGN), reported transactions on December 9, 2025.
• Schleifer acquired 172,723 shares of Common Stock by exercising non-qualified stock options at an exercise price of $555.67 per share.
• Concurrently, 155,145 shares of Common Stock were disposed of at a price of $701.51 per share, primarily to cover tax liabilities associated with the option exercise.
• Following these transactions, Schleifer directly owns 214,523 shares of Common Stock.
• Indirect beneficial ownership includes 127,484 shares via a 2024 GRAT, 300,000 shares via a 2025 GRAT, 5,989 shares via a 401(k) Plan, and 39,985 shares via a Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (option exercise and sell-to-cover) which is neutral in sentiment. It reflects the executive monetizing vested compensation rather than a specific positive or negative outlook on the company's immediate future.

Positives

• The exercise of stock options by a key executive indicates a continued belief in the company's value and future prospects, as the options were in-the-money.

Negatives

• The disposition of 155,145 shares, even for tax purposes, reduces the direct ownership stake of the CEO.

Future Outlook

NA

Industry Context

This Form 4 filing reports a routine insider transaction (option exercise and sell-to-cover) and does not provide broader industry context or trends. Such transactions are common for executives with equity compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and is unlikely to have a significant direct impact on the company's operational performance or strategic direction. It provides transparency into insider holdings.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of stock options and a subsequent sale of shares to cover tax liabilities. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment recommendation based solely on this report. Investors should continue to evaluate Regeneron based on its financial performance, pipeline, and market position.

Keywords

Regeneron Pharmaceuticals, REGN, Leonard S. Schleifer, Insider Transaction, Form 4, Stock Options, Equity Compensation, CEO